Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Dawn Warkentin"'
Autor:
James Gajewski, Issa F. Khouri, Borje S. Andersson, Sergio Giralt, Dawn Warkentin, Cindy Ippoliti, Rakesh Mehra, Donna Przepiorka, K. Van Besien, A. Morgan, Richard E. Champlin
Publikováno v:
Bone Marrow Transplantation. 20:491-495
Cytomegalovirus (CMV) disease can be prevented by administration of ganciclovir prophylactically post-transplant. However, up to 30% of patients discontinue use of ganciclovir as a result of profound neutropenia and may subsequently develop CMV infec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcce292add9ad192ec6bbce370058d21
https://doi.org/10.1038/sj.bmt.1700910
https://doi.org/10.1038/sj.bmt.1700910
Publikováno v:
Antimicrobial Agents and Chemotherapy. 40:904-908
MICs are commonly used to assess the in vitro activities of antimicrobial agents; however, they provide minimal information on the pattern of bacterial activities. Time-kill studies with extensive sampling allow assessment of both the rate and extent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73a06f101f04ec0a191dcca5d22caa06
https://doi.org/10.1128/aac.40.4.904
https://doi.org/10.1128/aac.40.4.904
Publikováno v:
JNCI Journal of the National Cancer Institute. 86:51-53
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ac1d3b609b365947d9485f5d119dfad
https://doi.org/10.1093/jnci/86.1.51
https://doi.org/10.1093/jnci/86.1.51
Autor:
Donna Przepiorka, Dawn Warkentin, Herbert A. Fritsche, Issa F. Khouri, M Woo, M. Korbling, Cindy Ippoliti
Publikováno v:
Bone marrow transplantation. 20(12)
To determine how well tacrolimus (FK506) and cyclosporin A (CsA) are tolerated after HLA-identical blood stem cell transplantation, we performed a retrospective review of 87 adults transplanted consecutively who received FK506 (n = 40) or CsA (n = 47
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02d82b987a33f3dd6a6b2ece36f169ff
https://pubmed.ncbi.nlm.nih.gov/9466284
https://pubmed.ncbi.nlm.nih.gov/9466284
Autor:
Donna E. Hogge, Donna L. Forrest, Yasser Abou Mourad, Raewyn Broady, Kevin W. Song, Heather J. Sutherland, John D. Shepherd, Cynthia L. Toze, Maryse M. Power, Thomas J. Nevill, Sujaatha Narayanan, Dawn Warkentin, Derek To, Michael J. Barnett, Stephen H. Nantel
Publikováno v:
Blood. 118:4567-4567
Abstract 4567 Reduced incidence of early invasive fungal infection in allogeneic transplant patients following micafungin prophylaxis. D To1, D Warkentin2, R Broady1, J. D. Shepherd1, S.H. Nantel1, T.J. Nevill1,C.M. Toze1, D.E. Hogge1, M.J. Barnett1,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f79f08ccffc12644a4b5b206284d0dc1
https://doi.org/10.1182/blood.v118.21.4567.4567
https://doi.org/10.1182/blood.v118.21.4567.4567
Autor:
Maryse M. Power, Clayton A. Smith, John D. Shepherd, Heather J. Sutherland, Winnie Ma, Thomas J. Nevill, Dawn Warkentin, Janice Yeung, Stephen H. Nantel, Michael J. Barnett, Kevin W. Song, Donna E. Hogge, Yasser Abou Mourad, Donna L. Forrest, Sujaatha Narayanan, Cynthia L. Toze
Publikováno v:
Blood. 114:1136-1136
Abstract 1136 Poster Board I-158 Introduction Invasive fungal infections (IFI) are associated with significant morbidity and mortality in hematopoietic stem cell transplant (HSCT) patients. Prophylaxis of high risk patient groups has become a key str
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93a4230875e3692898e1239cb847c6b1
https://doi.org/10.1182/blood.v114.22.1136.1136
https://doi.org/10.1182/blood.v114.22.1136.1136
Autor:
Michael J. Barnett, Stephen H. Nantel, Matthew J. Greenwood, Kevin W. Song, John D. Shepherd, Thomas J. Nevill, Richard T. Doocey, Dawn Warkentin, Janet Nitta, Donna L. Forrest, Clayton A. Smith, Julye C. Lavoie, Donna E. Hogge, Cynthia L. Toze, Heather J. Sutherland, Alan Le
Publikováno v:
Blood. 104:5092-5092
Steroid refractory aGVHD following allogeneic stem cell transplant (SCT) is associated with a long-term event-free survival (EFS) of less than 20%. Daclizumab is a humanised monoclonal antibody specific for the Tac subunit of the Interleukin-2 (IL-2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::256a523c54c5a5a17f9e77af4901e664
https://doi.org/10.1182/blood.v104.11.5092.5092
https://doi.org/10.1182/blood.v104.11.5092.5092
Autor:
Dawn Warkentin
Publikováno v:
Journal of Oncology Pharmacy Practice. 4:191-191
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12fe4271c3af5e975d41d9f947691f9c
https://doi.org/10.1177/107815529800400406
https://doi.org/10.1177/107815529800400406